$ACAD

ACADIA Pharmaceuticals (ACAD) received EU approval for DAYBU, its first treatment for Rett syndrome. The stock has risen 30% in 90 days, but fell 3.7% recently. Analysts suggest a 16% upside to $33.25, citing revenue growth and pipeline momentum, but note risks from R&D spending and clinical trial outcomes.

Acadia Pharmaceuticals (ACAD) received EU approval for DAYBU to treat Rett syndrome, based on Phase 3 trial data. This is the first authorized therapy for Rett syndrome in the EU, potentially opening a new market. The company is now in pricing and reimbursement negotiations. ACAD raised 2026 DAYBU sales guidance to $480M-$510M, with analysts projecting up to $1.9B in revenue. The approval strengthens ACAD's long-term diversification but near-term success depends on country-specific outcomes.

Acadia Pharmaceuticals (NASDAQ:ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. Management raised 2026 DAYBUE sales guidance to $480 million-$510 million and updated total revenue guidance to $1.24 billion-$1.30 billion. Cash and investments were $956 million as of June 30, 2026.

Acadia Pharmaceuticals said NUPLAZID saw 20% year-over-year growth in new-to-brand prescriptions, and a 40% expansion of its sales force increased targeted providers to about 10,000 to 10,500. For DAYBUE, the STIX formulation drove 60% of June prescriptions, alongside international expansion. Investors are awaiting Phase II remlifanserin Alzheimer’s psychosis data in September or October; Acadia has about $1B cash and is evaluating deals.

Acadia Pharmaceuticals (ACAD) outlined at Canaccord Genuity’s Growth Conference its commercial progress and pipeline. Management said NUPLAZID is at a $700 million annualized sales run rate, with 20% YoY growth in new-to-brand prescriptions, and DAYBUE STIX reached 60% of June prescriptions. Acadia has about $1 billion cash and expects Phase II/III remlifanserin Alzheimer’s disease psychosis data in Sep-Oct 2024.

Acadia Pharmaceuticals shares rose to a 52-week high around $29.76 to $29.81 and were about $29.77 at the time of reporting. The stock is up 36% over six months. Acadia reported Q2 2026 revenue of about $308 million versus a $296 million consensus, driven by Daybue sales of $125 million and steady Nuplazid. RBC, Oppenheimer, and Citizens raised price targets; analysts also cited upward earnings revisions and a Phase 2 RADIANT trial update.

Acadia Pharmaceuticals (ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. DAYBUE net sales were $125 million (+30%) and NUPLAZID net sales $183 million (+10%). 2026 sales guidance: DAYBUE $480-$510M, NUPLAZID $760-$790M, total revenue $1.24-$1.30B. Net income was $32M ($0.18/share).

Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold 20,141 shares of ACADIA PHARMACEUTICALS INC (ACAD) at an average of $29.16 ($29.00–$29.34, $0.59M total) across 3 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.

Acadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.

Acadia Pharmaceuticals (ACAD) shares rose 6.1% to $28.80 after earnings. For Q2 2026, revenue was $307.96 million (up from $264.57 million) and net income was $31.5 million (up from $26.67 million). The article cites a P/E of 13 and a DCF fair value estimate of $87.67 per share, with focus on DAYBUE, NUPLAZID and remlifanserin pipeline milestones.